HER2 测试市场：市场规模（按细分市场）、份额、监管、报销、预测（~2033 年）

乳癌是女性最常见的癌症，也是目前全球女性癌症相关死亡的主要原因。 2018年，报告了约1800万新发乳癌病例，新诊断病例约210万例，几乎占女性癌症病例的四分之一。

人类表皮生长因子受体 2 (HER2) 是一种跨膜酪胺酸激□受体，属于表皮生长因子受体 (EGFR) 家族。 此蛋白由位于 17 号染色体长臂 (17q12-21.32) 的 HER2 (ERBB2) 基因编码。 HER2 的不当活化与多种恶性肿瘤的发生有关，包括乳癌、胃癌、卵巢癌、大肠癌、胰臟癌和子宫内膜癌。 准确评估 HER2 状态对于确定最能从抗 HER2 标靶治疗中受益的患者至关重要。

在乳癌中，18% 至 20% 的患者出现 HER2 基因扩增。 另一方面，胃癌患者的 HER2 阳性率根据组织学亚型和部位的不同从 10% 到 30% 不等。

HER2检测模型包括HER2免疫组织化学（IHC）检测、HER2原位杂交（ISH）检测和HER2比较基因组杂交（aCGH）检测。

本报告深入探讨了全球 HER2 检测市场，包括竞争格局、SWOT 分析、到 2033 年的市场预测、COVID-19 的影响以及区域和国家趋势。Masu。

目录

目前HER2的市场测试及竞争状况

• 对主要产业趋势的见解
• 2015 年至 2033 年 HER2 测试按细分市场划分的市场总收入和市场前景
• 按细分市场划分的手术总数、单位数量、平均售价和市场价值的详细数据

全球、区域与国家见解

• HER2检测市场的SWOT分析
• HER2 检测市场的竞争动态洞察与趋势
• 各国医疗保健系统概览
• 按国家/地区划分的报销政策
• 各国医疗科技的监管状况

Abstract

HER2 Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on HER2 Tests market for the year 2020 and beyond. Breast cancer is the most frequent cancer in women and is now the leading cause of female cancer-related deaths worldwide. Approximately 18 million new breast cancer cases were reported in 2018, with approximately 2.1 million newly diagnosed cases, accounting for almost 1 in 4 cancer cases among women.

Human epidermal growth factor receptor 2 (HER2) is a transmembrane tyrosine kinase receptor belonging to the family of epidermal growth factor receptors (EGFRs). The protein is encoded by the HER2 (ERBB2) gene, which is located on the long arm of chromosome 17 (17q12-21.32). The inappropriate activation of HER2 is associated with the development of several malignancies, including breast, gastric, ovarian, colorectal, pancreatic, and endometrial cancers. An accurate evaluation of HER2 status is crucial for identification of patients who would most likely benefit from targeted anti-HER2 therapies.

In breast cancer, HER2 gene amplification, occurs in 18% to 20% of patients. On the other hand, the reported HER2 positivity in patients with gastric cancer ranges widely from 10% to 30% depending on the histologic subtype and location.

HER2 Tests model includes HER2 Immunohistochemistry (IHC) Tests, HER2 In Situ Hybridization (ISH) Tests and HER2 Comparative Genomic Hybridization (aCGH) Tests

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed HER2 Tests and evolving competitive landscape -

• Insightful review of the key industry trends.
• Annualized total HER2 tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights -

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for HER2 Tests market.
• Competitive dynamics insights and trends provided for HER2 Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Abbott Laboratories, Agilent Technologies Inc, Amoy Diagnostics Co Ltd, Biocare Medical LLC, Merck KGaA,F. Hoffmann-La Roche Ltd, Illumina Inc, Danaher Corp, medac GmbH, New England Biolabs Inc, Qiagen NV, Sysmex Corp, Thermo Fisher Scientific Inc, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the HER2 Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on HER2 Tests market.
• Develop and design you're in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving HER2 Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HER2 Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific HER2 Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Not Applicable

List of Tables

Not Applicable

List of Figures

Not Applicable